Natsumi Chatani

Natsumi Chatani

Auto-generated profile, based on publicly available information

Natsumi Chatani

Shionogi and Co Ltd

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
YNYoji Nagira
Yoji Nagira
MNMorio Nagira
Morio Nagira
RNRyohei Nagai
Ryohei Nagai
WNWataru Nogami
Wataru Nogami
MHMichinari Hirata
Michinari Hirata
HTHidekazu Tanaka
Hidekazu Tanaka
Although regulatory T cells (Treg) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing antitumor immunity. Selective reduction of tumor-infiltrating Tregs is, therefore, expected to activate antitumor immunity without affecting immune homeostasis. We previously reported that selective Treg depletion targeted by a C-C motif chemokine receptor 8 (CCR8) resulted in induction of strong antitumor immunity without any obvious autoimmunity in mouse models. Thus, herein, we developed a novel humanized anti-CCR8 monoclonal antibody, S-531011, aimed as a cancer immunotherapy strategy for patients with cancer. S-531011 exclusively recognized human CCR8 among all chemokine receptors and showed potent antibody-dependent cell-mediated cytotoxicity activity toward CCR8+ cells and neutralization activity against CCR8-mediated signaling. We observed that S-531011 reduced tumor-infiltrating CCR8+ Tregs and induced potent antitumor activity in a tumor-bearing human-CCR8 knock-in mouse model. Moreover, combination therapy with S-531011 and anti-mouse programmed cell death 1 (PD-1) antibody strongly suppressed tumor growth compared with anti–PD-1 antibody alone with no observable adverse effects. S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing antitumor immunity without severe side effects in the clinical setting.

24 September 2026 in Psychological Medicine
Verified
Journal Article
Open access
PDF file
YTYuko Toshishige
Yuko Toshishige
TOTakuya Okami
Takuya Okami
NCNatsumi Chatani
Natsumi Chatani
SKShiori Kawasaki
Shiori Kawasaki
SGShinobu Goto
Shinobu Goto
TATatsuo Akechi
Tatsuo Akechi
Background: Perinatal depression is a global health concern linked to adverse maternal and neonatal outcomes. Although evidence-based psychological interventions, such as interpersonal psychotherapy (IPT), are effective, women lack access to in-person perinatal care. Smartphone-based interventions may offer scalable support; however, evidence from randomized controlled trials (RCTs) evaluating IPT-informed smartphone interventions remains limited. This study assessed the acceptability and efficacy of an IPT-informed smartphone intervention for perinatal mental well-being. Methods: Participants were recruited nationwide through online advertisements and postcards. In this nonblinded RCT, 350 pregnant women were assigned to a fully self-guided smartphone application (intervention) or usual care (control). No minimum depression symptom score was required for participation. Acceptability in the intervention group at 8 weeks after enrolment was indicated by the Japanese version of the Client Satisfaction Questionnaire-8 (CSQ-8J) scores of ≥17. Efficacy was defined as the change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline to 8 weeks following enrolment. Depressive symptoms were assessed at 1 month postpartum. Results: The application achieved acceptability, with 90.2% (157/174) of participants scoring ≥17 on the CSQ-8J. No significant between-group differences in depressive symptoms were observed during pregnancy (standardized mean difference (SMD) = 0.11). At 1 month postpartum, the intervention group exhibited significantly lower depressive symptom scores (SMD = 0.28). Conclusions: The smartphone application was highly acceptable. While no significant differences in depressive symptoms were observed during pregnancy, differences favoring the intervention group were observed at 1 month postpartum. An IPT-informed smartphone intervention may represent a promising approach to perinatal mental health support.

6 September 2023
Verified
Other
Open access
YNYoji Nagira
Yoji Nagira
MNMorio Nagira
Morio Nagira
RNRyohei Nagai
Ryohei Nagai
WNWataru Nogami
Wataru Nogami
MHMichinari Hirata
Michinari Hirata
HTHidekazu Tanaka
Hidekazu Tanaka
Although regulatory T cells (Treg) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing antitumor immunity. Selective reduction of tumor-infiltrating Tregs is, therefore, expected to activate antitumor immunity without affecting immune homeostasis. We previously reported that selective Treg depletion targeted by a C-C motif chemokine receptor 8 (CCR8) resulted in induction of strong antitumor immunity without any obvious autoimmunity in mouse models. Thus, herein, we developed a novel humanized anti-CCR8 monoclonal antibody, S-531011, aimed as a cancer immunotherapy strategy for patients with cancer. S-531011 exclusively recognized human CCR8 among all chemokine receptors and showed potent antibody-dependent cell-mediated cytotoxicity activity toward CCR8+ cells and neutralization activity against CCR8-mediated signaling. We observed that S-531011 reduced tumor-infiltrating CCR8+ Tregs and induced potent antitumor activity in a tumor-bearing human-CCR8 knock-in mouse model. Moreover, combination therapy with S-531011 and anti-mouse programmed cell death 1 (PD-1) antibody strongly suppressed tumor growth compared with anti–PD-1 antibody alone with no observable adverse effects. S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing antitumor immunity without severe side effects in the clinical setting.

10 August 2023
Verified
Other
Open access
YNYoji Nagira
Yoji Nagira
MNMorio Nagira
Morio Nagira
RNRyohei Nagai
Ryohei Nagai
WNWataru Nogami
Wataru Nogami
MHMichinari Hirata
Michinari Hirata
HTHidekazu Tanaka
Hidekazu Tanaka
In vivo anti-tumor activity of S-531011 in CT26.WT or EMT6 tumor-bearing mice model.


10 August 2023
Verified
Other
Open access
YNYoji Nagira
Yoji Nagira
MNMorio Nagira
Morio Nagira
RNRyohei Nagai
Ryohei Nagai
WNWataru Nogami
Wataru Nogami
MHMichinari Hirata
Michinari Hirata
HTHidekazu Tanaka
Hidekazu Tanaka
The binding activity of S-531011 against various chemokine receptors, PD-1, PD-L1, CTLA4, or mouse CCR8